Cannabidiol effects on prepulse inhibition in nonhuman primates

References

Ahmari, S.E., Risbrough, V.B., Geyer, M.A., and Simpson, H.B. (2012). Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology 37, 1216–1223.10.1038/npp.2011.308Search in Google Scholar PubMed

Ahmari, S.E., Risbrough, V.B., Geyer, M.A., and Simpson, H.B. (2016). Prepulse inhibition deficits in obsessive compulsive disorder are more pronounced in females. Neuropsychopharmacology 41, 2963–2964.10.1038/npp.2015.363Search in Google Scholar PubMed

Auclair, A.L., Kleven, M.S., Barret-Grévoz, C., Barreto, M., Newman-Tancredi, A., and Depoortère, R. (2009). Differences among conventional, atypical and novel putative D2/5-HT1A antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys. Behav. Brain Res. 203, 288–295.10.1016/j.bbr.2009.05.015Search in Google Scholar

Baker, D., Pryce, G., Giovannoni, G., and Thompson, A.J. (2003). The therapeutic potential of cannabis. Lancet Neurol. 2, 291–298.10.1016/S1474-4422(03)00381-8Search in Google Scholar PubMed

Bakshi, V.P. and Geyer, M.A. (1998). Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 18, 8394–8401.10.1523/JNEUROSCI.18-20-08394.1998Search in Google Scholar PubMed

Berardelli, A., Rothwell, J.C., Day, B.L., and Marsden, C.D. (1985). Pathophysiology of blepharospasm and oromandibular dystonia. Brain 108, 593–608.10.1093/brain/108.3.593Search in Google Scholar PubMed

Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’Carroll, C.M., Seal, M., Allen, P., et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764–774.10.1038/npp.2009.184Search in Google Scholar PubMed

Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Aniello, I.B., Moriello, S., Davis, J.B., Mechoulam, R., and Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845–852.10.1038/sj.bjp.0704327Search in Google Scholar PubMed

Boyce, S., Rupniak, N.M., Steventon, M.J., Cook, G., and Iversen, S.D. (1991). Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primates. Behav. Brain Res. 42, 115–121.10.1016/S0166-4328(05)80002-6Search in Google Scholar PubMed

Braff, D., Stone, C., Callaway, E., Geyer, M., Glick, I., and Bali, L. (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15, 339–343.10.1111/j.1469-8986.1978.tb01390.xSearch in Google Scholar PubMed

Braff, D.L., Geyer, M.A., Light, G.A., Sprock, J., Perry, W., Cadenhead, K.S., and Swerdlow, N.R. (2001a). Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr. Res. 49, 171–178.10.1016/S0920-9964(00)00139-0Search in Google Scholar

Braff, D.L., Geyer, M.A., and Swerdlow, N.R. (2001b). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.) 156, 234–258.10.1007/s002130100810Search in Google Scholar

Campos, A.C. and Guimarães, F.S. (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl.) 199, 223–230.10.1007/s00213-008-1168-xSearch in Google Scholar PubMed

Campos, A.C., Fogaça, M.V., Sonego, A.B., and Guimarães, F.S. (2016). Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 112, 119–127.10.1016/j.phrs.2016.01.033Search in Google Scholar PubMed

Carlini, E.A. and Cunha, J.M. (1981). Hypnotic and antiepileptic effects of cannabidiol. Clin. Pharmacol. 21, 417–427.10.1002/j.1552-4604.1981.tb02622.xSearch in Google Scholar

Castellanos, F.X., Fine, E.J., Kaysen, D., Marsh, W.L., Rapoport, J.L., and Hallett, M. (1996). Sensorimotor gating in boys with Tourette’s syndrome and ADHD: preliminary results. Biol. Psychiatry 39, 33–41.10.1016/0006-3223(95)00101-8Search in Google Scholar PubMed

Chan, W.Y.M. and McNally, G.P. (2009). Conditioned stimulus familiarity determines effects of MK-801 on fear extinction. Behav. Neurosci. 123, 303–314.10.1037/a0014988Search in Google Scholar PubMed

Console-Bram, L., Marcu, J., and Abood, M.E. (2012). Cannabinoid receptors: nomenclature and pharmacological principles. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 38, 4–15.10.1016/j.pnpbp.2012.02.009Search in Google Scholar PubMed PubMed Central

Crippa, J.A.D.S., Zuardi, A.W., Garrido, G.E.J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P.M., Hallak, J.E., McGuire, P.K., and Filho Busatto, G. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29, 417–426.10.1038/sj.npp.1300340Search in Google Scholar PubMed

Crippa, J.A.S., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L.S., Martin-Santos, R., Simões, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25, 121–130.10.1177/0269881110379283Search in Google Scholar PubMed

Crippa, J.A.S., Crippa, A.C.S., Hallak, J.E.C., Martín-Santos, R., and Zuardi, A.W. (2016). Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front. Pharmacol. 7, 1–6.10.3389/fphar.2016.00359Search in Google Scholar

Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., and Di Marzo, V. (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139, 1405–1415.10.1016/j.neuroscience.2006.02.074Search in Google Scholar PubMed

Dahmen, J.C. and Corr, P. J. (2004). Prepulse-elicited startle in prepulse inhibition. Biol. Psychiatry 55, 98–101.10.1016/S0006-3223(03)00638-3Search in Google Scholar PubMed

Davis, M., Gendelman, D.S., Tischler, M.D., and Gendelman, P.M. (1982). A primary acoustic startle circuit: lesion and stimulation studies. J. Neurosci. 2, 791–805.10.1523/JNEUROSCI.02-06-00791.1982Search in Google Scholar PubMed

Davis, M., Antoniadis, E.A., Amaral, D.G., and Winslow, J.T. (2008). Acoustic startle reflex in Rhesus monkeys: a review. Rev. Neurosci. 19, 171–185.10.1515/REVNEURO.2008.19.2-3.171Search in Google Scholar PubMed

Dean, B., Sundram, S., Bradbury, R., Scarr, E., and Copolov, D.D. (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9–15.10.1016/S0306-4522(00)00552-2Search in Google Scholar PubMed

De Petrocellis, L., Cascio, M.G., and Di Marzo, V. (2004). The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141, 765–774.10.1038/sj.bjp.0705666Search in Google Scholar PubMed

Deutsch, S.I., Rosse, R.B., Schwartz, B.L., and Mastropaolo, J. (2001). A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 24, 43–49.10.1097/00002826-200101000-00008Search in Google Scholar PubMed

Di Marzo, V. and Matias, I. (2005). Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8, 585–589.10.1038/nn1457Search in Google Scholar PubMed

Di Marzo, V., Bisogno, T., and De Petrocellis, L. (2001). Anandamide: some like it hot. Trends Pharmacol. Sci. 22, 346–349.10.1016/S0165-6147(00)01712-0Search in Google Scholar PubMed

Di Marzo, V., Bifulco, M., and De Petrocellis, L. (2004). The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771–784.10.1038/nrd1495Search in Google Scholar PubMed

Do Val-da Silva, R.A., Peixoto-Santos, J.E., Kandratavicius, L., de Ross, J.B., Esteves, I., de Martinis, B.S., Alves, M.N.R., Scandiuzzi, R.C., Hallak, J.E.C., Zuardi, A.W., et al. (2017). Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy. Front. Pharmacol. 8, 1–15.10.3389/fphar.2017.00131Search in Google Scholar

Duncan, E.J., Madonick, S.H., Parwani, A., Angrist, B., Rajan, R., Chawravorty, S., Efferen, T.R., Szilagyi, S., Stephanides, M., Chappell, P.B., et al. (2001). Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25, 72–83.10.1016/S0893-133X(00)00240-2Search in Google Scholar PubMed

Eggan, S.M. and Lewis, D.A. (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb. Cortex 17, 175–191.10.1093/cercor/bhj136Search in Google Scholar PubMed

Ennaceur, A., Michalikova, S., Van Rensburg, R., and Chazot, P.L. (2011). MK-801 increases the baseline level of anxiety in mice introduced to a spatial memory task without prior habituation. Neuropharmacology 61, 981–991.10.1016/j.neuropharm.2011.06.027Search in Google Scholar PubMed

Geyer, M. and Mansbach, R. (1989). Disruption of prepulse inhibition of acoustic startile in rats by phencyclidine and MK801. Schizophr. Res. 2, 186.10.1016/0920-9964(89)90222-3Search in Google Scholar

Geyer, M.A., Krebs-Thomson, K., Braff, D.L., and Swerdlow, N.R. (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156, 117–154.10.1007/s002130100811Search in Google Scholar PubMed

Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., and Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108–2114.10.1038/sj.npp.1300558Search in Google Scholar PubMed

Glass, M. (2001). The role of cannabinoids in neurodegenerative diseases. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25, 743–765.10.1016/S0278-5846(01)00162-2Search in Google Scholar

Gomes, F.V., Issy, A.C., Ferreira, F.R., Viveros, M.-P., Del Bel, E.A., and Guimaraes, F.S. (2015). Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int. J. Neuropsychopharmacol. 18, 1–10.10.1093/ijnp/pyu041Search in Google Scholar PubMed PubMed Central

Gómez-Wong, E., Martí, M.J., Tolosa, E., and Valls-Solé, J. (1998). Sensory modulation of the blink reflex in patients with blepharospasm. Arch. Neurol. 55, 1233–1237.10.1001/archneur.55.9.1233Search in Google Scholar PubMed

Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, P.A., Brusco, A., and Uhl, G.R. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 10–23.10.1016/j.brainres.2005.11.035Search in Google Scholar PubMed

Grillon, C., Ameli, R., Charney, D.S., Krystal, J., and Braff, D. (1992). Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 32, 939–943.10.1016/0006-3223(92)90183-ZSearch in Google Scholar PubMed

Gururajan, A., Taylor, D.A., and Malone, D.T. (2011). Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav. Brain Res. 222, 299–308.10.1016/j.bbr.2011.03.053Search in Google Scholar PubMed

Hampson, A.J., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268–8273.10.1073/pnas.95.14.8268Search in Google Scholar PubMed PubMed Central

Hoenig, K., Hochrein, A., Quednow, B.B., Maier, W., and Wagner, M. (2005). Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biol. Psychiatry 57, 1153–1158.10.1016/j.biopsych.2005.01.040Search in Google Scholar PubMed

Hurd, Y.L., Yoon, M., Manini, A.F., Hernandez, S., Olmedo, R., Ostman, M., and Jutras-Aswad, D. (2015). Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 12, 807–815.10.1007/s13311-015-0373-7Search in Google Scholar PubMed PubMed Central

Izquierdo, I., Orsingher, O.A., and Berardi, A.C. (1973). Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia 28, 95–102.10.1007/BF00413961Search in Google Scholar PubMed

Javitt, D.C. and Lindsley, R.W. (2001). Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychopharmacology (Berl.) 156, 165–168.10.1007/s002130100758Search in Google Scholar PubMed

Jones, N.A., Glyn, S.E., Akiyama, S., Hill, T.D.M., Hill, A.J., Weston, S.E., Burnett, M.D., Yamasaki, Y., Stephens, G.J., Whalley, B.J., et al. (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21, 344–352.10.1016/j.seizure.2012.03.001Search in Google Scholar PubMed

Judd, L.L., McAdams, L., Budnick, B., and Braff, D.L. (1992). Sensory gating deficits in schizophrenia: new results. Am. J. Psychiatry 149, 488–493.10.1176/ajp.149.4.488Search in Google Scholar PubMed

Jurkus, R., Day, H.L.L., Guimaraes, F.S., Lee, J.L.C., Bertoglio, L.J., and Stevenson, C.W. (2016). Cannabidiol regulation of learned fear: implications for treating anxiety-related disorders. Front. Pharmacol. 7, 1–8.10.3389/fphar.2016.00454Search in Google Scholar

Koch, M. (1999). The neurobiology of startle. Prog. Neurobiol. 59, 107–128.10.1016/S0301-0082(98)00098-7Search in Google Scholar PubMed

Kohl, S., Heekeren, K., Klosterkötter, J., and Kuhn, J. (2013). Prepulse inhibition in psychiatric disorders – apart from schizophrenia. J. Psychiatr. Res. 47, 445–452.10.1016/j.jpsychires.2012.11.018Search in Google Scholar PubMed

Kumari, V., Soni, W., and Sharma, T. (1999). Normalization of information processing deficits in schizophrenia with clozapine. Am. J. Psychiatry 156, 1046–1051.10.1176/ajp.156.7.1046Search in Google Scholar PubMed

Lang, P.J., Bradley, M.M., and Cuthbert, B.N. (1990). Emotion, attention, and the startle reflex. Psychol. Rev. 97, 377–395.10.1037/0033-295X.97.3.377Search in Google Scholar PubMed

Lee, J.L.C., Bertoglio, L.J., Guimaraes, F.S., and Stevenson, C.W. (2017). Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br. J. Pharmacol. 174, 3242–3256.10.1111/bph.13724Search in Google Scholar PubMed PubMed Central

Levin, R., Peres, F.F., Almeida, V., Calzavara, M.B., Zuardi, A.W., Hallak, J.E.C., Crippa, J.A.S, and Abílio, V.C. (2014). Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. Front. Pharmacol. 5, 1–10.10.3389/fphar.2014.00010Search in Google Scholar PubMed PubMed Central

Leweke, F.M., Giuffrida, A., Wurster, U., Emrich, H.M., and Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665–1669.10.1097/00001756-199906030-00008Search in Google Scholar PubMed

Leweke, F.M., Gerth, C.W., and Klosterkötter, J. (2004). Cannabis-associated psychosis: current status of research. CNS Drugs 18, 895–910.10.2165/00023210-200418130-00005Search in Google Scholar PubMed

Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkötter, J., Hellmich, M., and Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2, e94.10.1038/tp.2012.15Search in Google Scholar PubMed PubMed Central

Li, L., Korngut, L.M., Frost, B.J., and Beninger, R.J. (1998). Prepulse inhibition following lesions of the inferior colliculus: prepulse intensity functions. Physiol. Behav. 65, 133–139.10.1016/S0031-9384(98)00143-7Search in Google Scholar PubMed

Linn, G.S. and Javitt, D.C. (2001). Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 12, 117–120.10.1097/00001756-200101220-00031Search in Google Scholar PubMed

Linn, G.S., Negi, S.S., Gerum, S.V., and Javitt, D.C. (2003). Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl). 169, 234–239.10.1007/s00213-003-1533-8Search in Google Scholar PubMed

Long, L.E., Malone, D.T., and Taylor, D.A. (2006). Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31, 795–803.10.1038/sj.npp.1300838Search in Google Scholar PubMed

Ludewig, S., Ludewig, K., Geyer, M.a., Hell, D., and Vollenweider, F.X. (2002). Prepulse inhibition deficits in patients with panic disorder. Depress. Anxiety 15, 55–60.10.1002/da.10026Search in Google Scholar PubMed

Ludewig, S., Geyer, M.A., Ramseier, M., Vollenweider, F.X., Rechsteiner, E., and Cattapan-Ludewig, K. (2005). Information-processing deficits and cognitive dysfunction in panic disorder. J. Psychiatry Neurosci. 30, 37–43.Search in Google Scholar PubMed

Lutz, B., Marsicano, G., Maldonado, R., and Hillard, C.J. (2015). The endocannabinoid system in guarding against fear, anxiety and stress. Nat. Rev. Neurosci. 16, 705–718.10.1038/nrn4036Search in Google Scholar PubMed PubMed Central

Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., and Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 97, 9561–9566.10.1073/pnas.160105897Search in Google Scholar PubMed PubMed Central

Mansbach, R.S. and Geyer, M.A. (1991). Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl.) 105, 162–168.10.1007/BF02244303Search in Google Scholar PubMed

Marinho, A.L.Z., Vila-Verde, C., Fogaça, M.V., and Guimarães, F.S. (2015). Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: contribution of 5HT1A receptors and stressful experiences. Behav. Brain Res. 286, 49–56.10.1016/j.bbr.2015.02.023Search in Google Scholar PubMed

Mechoulam, R., Parker, L.A., and Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11S–19S.10.1002/j.1552-4604.2002.tb05998.xSearch in Google Scholar PubMed

Munro, S., Thomas, K.L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65.10.1038/365061a0Search in Google Scholar PubMed

Newell, K.A., Deng, C., and Huang, X.F. (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 172, 556–560.10.1007/s00221-006-0503-xSearch in Google Scholar PubMed

Osborne, A.L., Solowij, N., and Weston-Green, K. (2017). A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci. Biobehav. Rev. 72, 310–324.10.1016/j.neubiorev.2016.11.012Search in Google Scholar PubMed

Otnaess, M.K., Brun, V.H., Moser, M.B., and Moser, E.I. (1999). Pretraining prevents spatial learning impairment after saturation of hippocampal long-term potentiation. J. Neurosci. 19, 1–5.10.1523/JNEUROSCI.19-24-j0007.1999Search in Google Scholar

Pacher, P., Bátkai, S., Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58, 389–462.10.1124/pr.58.3.2Search in Google Scholar PubMed

Pedrazzi, J.F.C., Issy, A.C., Gomes, F.V., Guimarães, F.S., and Del-Bel, E.A. (2015). Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl.) 232, 3057–3065.10.1007/s00213-015-3945-7Search in Google Scholar PubMed

Peres, F.F., Levin, R., Almeida, V., Zuardi, W.A., Hallak, J.E., Crippa, J.A., and Abílio, V. (2016). Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy. Front. Pharmacol. 7, 303.10.3389/fphar.2016.00303Search in Google Scholar PubMed

Peres, F.F., Almeida, V., and Abilio, V.C. (2017). Cannabidiol: an overview of its antipsychotic properties. Handbook of Cannabis and Related Pathologies. V.R. Preedy, ed. Biol. Pharmacol. Diagn. Treat. 787–794.10.1016/B978-0-12-800756-3.00092-2Search in Google Scholar

Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4, 873–884.10.1038/nrn1247Search in Google Scholar PubMed

Reijmers, L.G., Vanderheyden, P.M., and Peeters, B.W. (1995). Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur. J. Pharmacol. 272, 131–138.10.1016/0014-2999(94)00629-LSearch in Google Scholar PubMed

Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C.V., and Hurd, Y.L. (2009). Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J. Neurosci. 29, 14764–14769.10.1523/JNEUROSCI.4291-09.2009Search in Google Scholar PubMed

Resstel, L.B.M., Tavares, R.F., Lisboa, S.F.S., Joca, S.R.L., Corrêa, F.M.A., and Guimarães, F.S. (2009). 5-HT 1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol. 156, 181–188.10.1111/j.1476-5381.2008.00046.xSearch in Google Scholar PubMed

Robson, P.J., Guy, G.W., and Di Marzo, V. (2014). Cannabinoids and schizophrenia: therapeutic prospects. Curr. Pharm. Des. 20, 2194–2204.10.2174/13816128113199990427Search in Google Scholar PubMed

Rock, E.M., Limebeer, C.L., Petrie, G.N., Williams, L.A., Mechoulam, R., and Parker, L.A. (2017). Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology (Berl.) 234, 2207–2217.10.1007/s00213-017-4626-5Search in Google Scholar PubMed

Roesler, R., Vianna, M., Sant’Anna, M.K., Kuyven, C.R., Kruel, A.V, Quevedo, J., and Ferreira, M.B. (1998). Intrahippocampal infusion of the NMDA receptor antagonist AP5 impairs retention of an inhibitory avoidance task: protection from impairment by pretraining or preexposure to the task apparatus. Neurobiol. Learn. Mem. 69, 87–91.10.1006/nlme.1997.3810Search in Google Scholar PubMed

Rupniak, N.M.J., Boyce, S., Steventon, M.J., Iversen, S.D., and Marsden, C.D. (1992). Dystonia induced by combined treatment with l-dopa and MK-801 in parkinsonian monkeys. Ann. Neurol. 32, 103–105.10.1002/ana.410320118Search in Google Scholar PubMed

Saletti, P.G., Maior, R.S., Hori, E., Almeida, R.M.De, Nishijo, H., and Tomaz, C. (2014). Whole-body prepulse inhibition protocol to test sensorymotor gating mechanisms in monkeys. PLoS One 9, e105551.10.1371/journal.pone.0105551Search in Google Scholar PubMed

Saletti, P.G., Maior, R.S., Hori, E., Nishijo, H., and Tomaz, C. (2015). Sensorimotor gating impairments induced by MK-801 treatment may be reduced by tolerance effect and by familiarization in monkeys. Front. Pharmacol. 6, 204.10.3389/fphar.2015.00204Search in Google Scholar PubMed

Saletti, P.G., Maior, R.S., Barros, M., Nishijo, H., and Tomaz, C. (2017). Cannabidiol affects MK-801-induced changes in the PPI learned response of capuchin monkeys (Sapajus spp.). Front. Pharmacol. 8, 1–7.10.3389/fphar.2017.00093Search in Google Scholar

Sanders, M.J. and Fanselow, M.S. (2003). Pre-training prevents context fear conditioning deficits produced by hippocampal NMDA receptor blockade. Neurobiol. Learn. Mem. 80, 123–129.10.1016/S1074-7427(03)00040-6Search in Google Scholar PubMed

Saucier, D., Hargreaves, E.L., Boon, F., Vanderwolf, C.H., and Cain, D.P. (1996). Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates spatial learning deficits. Behav. Neurosci. 110, 103–116.10.1037/0735-7044.110.1.103Search in Google Scholar PubMed

Schulz, B., Fendt, M., Pedersen, V., and Koch, M. (2001). Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine. Psychopharmacology (Berl.) 156, 177–181.10.1007/s002130100776Search in Google Scholar PubMed

Seillier, A. and Giuffrida, A. (2009). Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav. Brain Res. 204, 410–415.10.1016/j.bbr.2009.02.007Search in Google Scholar PubMed

Shannon, S. and Opila-Lehman, J. (2016). Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm. J. 20, 108–111.10.7812/TPP/16-005Search in Google Scholar PubMed

Shapiro, M.L. and O’Connor, C. (1992). N-methyl-D-aspartate receptor antagonist MK-801 and spatial memory representation: working memory is impaired in an unfamiliar environment but not in a familiar environment. Behav. Neurosci. 106, 604–612.10.1037/0735-7044.106.4.604Search in Google Scholar

Steinman, S.A., Ahmari, S.E., Choo, T., Kimeldorf, M.B., Feit, R., Loh, S., Risbrough, V., Geyer, M.A., Steinglass, J.E., Wall, M., et al. (2016). Prepulse inhibition deficits only in females with obsessive-compulsive disorder. Depress. Anxiety 33, 238–246.10.1002/da.22474Search in Google Scholar PubMed

Swerdlow, N.R., Benbow, C.H., Zisook, S., Geyer, M.A., and Braff, D.L. (1993). A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol. Psychiatry 33, 298–301.10.1016/0006-3223(93)90300-3Search in Google Scholar PubMed

Swerdlow, N.R., Karban, B., Ploum, Y., Sharp, R., Geyer, M.A., and Eastvold, A. (2001). Tactile prepuff inhibition of startle in children with Tourette’s syndrome: in search of an “fMRI-friendly” startle paradigm. Biol. Psychiatry 50, 578–585.10.1016/S0006-3223(01)01164-7Search in Google Scholar PubMed

Swerdlow, N.R., Light, G.A., Thomas, M.A., Sprock, J., Calkins, M.E., Green, M.F., Greenwood, T.A., Gur, R.E., Gur, R.C., Lazzeroni, L.C., et al. (2017). Deficient prepulse inhibition in schizophrenia in a multi-site cohort: internal replication and extension.Schizophrenia Res. pii: S0920-9964(17)30272-4.10.1016/j.schres.2017.05.013Search in Google Scholar PubMed PubMed Central

Tamir, I., Mechoulam, R., and Meyer, A.Y. (1980). Cannabidiol and phenytoin: a structural comparison. J. Med. Chem. 23, 220–223.10.1021/jm00176a022Search in Google Scholar PubMed

Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., and Pertwee, R.G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613–623.10.1038/sj.bjp.0707133Search in Google Scholar PubMed

Uekita, T. and Okaichi, H. (2005). NMDA antagonist MK-801 does not interfere with the use of spatial representation in a familiar environment. Behav. Neurosci. 119, 548–556.10.1037/0735-7044.119.2.548Search in Google Scholar

Vigano, D., Guidali, C., Petrosino, S., Realini, N., Rubino, T., Di Marzo, V., and Parolaro, D. (2009). Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int. J. Neuropsychopharmacol. 12, 599–614.10.1017/S1461145708009371Search in Google Scholar PubMed

Volk, D.W. and Lewis, D.A. (2016). The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia. Biol. Psychiatry 79, 595–603.10.1016/j.biopsych.2015.06.015Search in Google Scholar PubMed

Warf, B. (2014). High points: an historical geography of cannabis. Geogr. Rev. 104, 414–438.10.1111/j.1931-0846.2014.12038.xSearch in Google Scholar

Weike, A.I., Bauer, U., and Hamm, A.O. (2000). Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol. Psychiatry 47, 61–70.10.1016/S0006-3223(99)00229-2Search in Google Scholar PubMed

Winslow, J.T., Parr, L.A., and Davis, M. (2002). Acoustic startle, prepulse inhibition, and fear-potentiated startle measured in rhesus monkeys. Biol. Psychiatry. 51, 859–866.10.1016/S0006-3223(02)01345-8Search in Google Scholar PubMed

Winslow, J.T., Noble, P.L., and Davis, M. (2007). Modulation of fear-potentiated startle and vocalizations in juvenile rhesus monkeys by morphine, diazepam, and buspirone. Biol. Psychiatry 61, 389–395.10.1016/j.biopsych.2006.03.012Search in Google Scholar PubMed

Wolf, R., Dobrowolny, H., Matzke, K., Paelchen, K., Bogerts, B., and Schwegler, H. (2006). Prepulse inhibition is different in two inbred mouse strains (CPB-K and BALB/cJ) with different hippocampal NMDA receptor densities. Behav Brain Res. 166, 78–84.10.1016/j.bbr.2005.07.027Search in Google Scholar PubMed

Xing, J. and Li, J. (2007). TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J. Neurophysiol. 97, 503–511.10.1152/jn.01023.2006Search in Google Scholar PubMed

Zavitsanou, K., Garrick, T., and Huang, X.F. (2004). Selective antagonist [³H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuro-Psychopharmacology Biol. Psychiatry 28, 355–360.10.1016/j.pnpbp.2003.11.005Search in Google Scholar PubMed

Zuardi, A.W., Shirakawa, I., Finkelfarb, E., and Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology (Berl.) 76, 245–250.10.1007/BF00432554Search in Google Scholar PubMed

Zuardi, A.W., Antunes Rodrigues, J., and Cunha, J.M. (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl.) 104, 260–264.10.1007/BF02244189Search in Google Scholar PubMed

Zuardi, A.W., Crippa, J.A., Hallak, J.E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., McGuire, P.K., and Guimarães, F.S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm. Des. 18, 5131–5140.10.2174/138161212802884681Search in Google Scholar PubMed